414 related articles for article (PubMed ID: 24667963)
21. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
Song DG; Ye Q; Santoro S; Fang C; Best A; Powell DJ
Hum Gene Ther; 2013 Mar; 24(3):295-305. PubMed ID: 23297870
[TBL] [Abstract][Full Text] [Related]
22. Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR.
Li Z; Chi Z; Ang WX; Chen C; Tay JC; Ng YY; Xu X; Wang J; Zhu J; Wang S
Immunotherapy; 2020 Jul; 12(10):733-748. PubMed ID: 32571133
[No Abstract] [Full Text] [Related]
23. Co-expression of IL-4/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment.
Zhou Y; Farooq MA; Ajmal I; He C; Gao Y; Guo D; Duan Y; Jiang W
Biomed Pharmacother; 2023 Dec; 168():115740. PubMed ID: 37865999
[TBL] [Abstract][Full Text] [Related]
24. Exploiting natural killer group 2D receptors for CAR T-cell therapy.
Demoulin B; Cook WJ; Murad J; Graber DJ; Sentman ML; Lonez C; Gilham DE; Sentman CL; Agaugue S
Future Oncol; 2017 Aug; 13(18):1593-1605. PubMed ID: 28613086
[TBL] [Abstract][Full Text] [Related]
25. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
26. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells.
Abken H
Hum Gene Ther; 2017 Nov; 28(11):1047-1060. PubMed ID: 28810803
[TBL] [Abstract][Full Text] [Related]
27. NKG2D ligands as therapeutic targets.
Spear P; Wu MR; Sentman ML; Sentman CL
Cancer Immun; 2013; 13():8. PubMed ID: 23833565
[TBL] [Abstract][Full Text] [Related]
28. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
Ding H; Yang X; Wei Y
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
[TBL] [Abstract][Full Text] [Related]
29. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
[TBL] [Abstract][Full Text] [Related]
30. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract][Full Text] [Related]
31. NKG2D and its ligands in cancer.
Dhar P; Wu JD
Curr Opin Immunol; 2018 Apr; 51():55-61. PubMed ID: 29525346
[TBL] [Abstract][Full Text] [Related]
32. Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer.
Zhang Y; Li X; Zhang J; Mao L
Biomed Pharmacother; 2020 Nov; 131():110562. PubMed ID: 32920508
[TBL] [Abstract][Full Text] [Related]
33. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.
Zhang T; Sentman CL
J Immunol; 2013 Mar; 190(5):2455-63. PubMed ID: 23355740
[TBL] [Abstract][Full Text] [Related]
34. Annihilation of Non-small Cell Lung Cancer by NKG2D CAR-T Cells Produced from T Cells from Peripheral Blood of Healthy Donors.
Jiang J; Liu Y; Zeng Y; Fang B; Chen Y
J Interferon Cytokine Res; 2023 Oct; 43(10):445-454. PubMed ID: 37819621
[TBL] [Abstract][Full Text] [Related]
35. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
[TBL] [Abstract][Full Text] [Related]
36. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.
Leivas A; Valeri A; Córdoba L; García-Ortiz A; Ortiz A; Sánchez-Vega L; Graña-Castro O; Fernández L; Carreño-Tarragona G; Pérez M; Megías D; Paciello ML; Sánchez-Pina J; Pérez-Martínez A; Lee DA; Powell DJ; Río P; Martínez-López J
Blood Cancer J; 2021 Aug; 11(8):146. PubMed ID: 34392311
[TBL] [Abstract][Full Text] [Related]
37. Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells.
Guo C; Wang X; Zhang H; Zhi L; Lv T; Li M; Lu C; Zhu W
Mol Immunol; 2019 Oct; 114():108-113. PubMed ID: 31351411
[TBL] [Abstract][Full Text] [Related]
38. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
39. The NKG2D axis: an emerging target in cancer immunotherapy.
Lazarova M; Steinle A
Expert Opin Ther Targets; 2019 Apr; 23(4):281-294. PubMed ID: 30732494
[TBL] [Abstract][Full Text] [Related]
40. 'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors.
Gilham DE; Maher J
Immunotherapy; 2017 Aug; 9(9):723-733. PubMed ID: 28771104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]